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Abstract
The 22q11.2 deletion syndrome is one of the most common deletion syndromes in newborns. 
Some affected newborns may be diagnosed shortly after birth because of the presence of heart 
defects, palatal defects, or severe immune deficiencies. However, diagnosis is often delayed in 
patients presenting with other associated conditions that would benefit from early recognition and 
treatment, such as speech delays, learning difficulties, and schizophrenia. Fluorescence in situ 
hybridization (FISH) is the gold standard for deletion detection, but it is costly and time 
consuming and requires a whole blood specimen. Our goal was to develop a suitable assay for 
population-based screening of easily collectible specimens, such as buccal swabs and dried blood 
spots (DBS). We designed a pyrosequencing assay and validated it using DNA from FISH–
confirmed 22q11 deletion syndrome patients and normal controls. We tested DBS from nine 
patients and paired buccal cell and venous blood specimens from 20 patients. Results were 100% 
concordant with FISH assay results. DNA samples from normal controls (n = 180 cell lines, n = 15 
DBS, and n = 88 buccal specimens) were negative for the deletion. Limiting dilution experiments 
demonstrated that accurate results could be obtained from as little as 1 ng of DNA. This method 
represents a reliable and low-cost alternative for detection of the common 22q11.2 microdeletions 
and can be adapted to high-throughput population screening.
The 22q11.2 deletion syndrome (22q11DS), alias DiGeorge syndrome (DGS), shprintzen 
syndrome, and velocardiofacial syndrome, is estimated to be the most common inheritable 
genetic deletion syndrome, with a reported prevalence ranging from approximately 1:9700 
to as high as 1:3900 live births.1,2 This syndrome is the result of hemizygous deletions of 
chromosome 22q11.2, with a 3-Mb deletion representing most (approximately 90%) of all 
deletions.3 Approximately 7% of cases are accounted for by the smaller 1.5-Mb deletion 
nested within the 3-Mb region, with the remaining 3% consisting of various other 
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microdeletions.3 Clinical presentation is highly variable, and there is often poor correlation 
between genotype and phenotype. In addition, lesser-known microduplications, which are 
presumed to be reciprocal rearrangements to the microdeletions characterized in the 22q11.2 
region, generally result in milder, yet highly variable, phenotypes.4 Well-designed, 
population-based studies are needed for a more comprehensive evaluation of the impact, 
distribution, and clinical presentation of this highly dynamic 22q11.2 region.
The current gold standard clinical laboratory assay for 22q11DS uses the TUPLE 
fluorescence in situ hybridization (FISH) probe, which is located in the common 3-Mb 
deletion and in the less common 1.5-Mb nested deletion. FISH is costly, requires a whole 
blood sample, and takes at least 48 hours to perform. This makes the test feasible as a 
diagnostic test only for those patients for whom it is clinically warranted. Alternative 
molecular technologies, such as multiplex ligation-dependent probe amplification 
(MLPA),5–8 microsatellite marker analysis,6 and real-time quantitative PCR,9–11 have been 
developed for possible use as population screening tests in the diagnosis of 22q11DS. 
Although economically more cost-effective and less labor intensive than FISH, some 
methods are still technologically challenging, data analysis is not always straightforward, 
and the high costs of commercial kits or expensive fluorescent dye-labeled probes may make 
higher-throughput screening cost prohibitive. In addition, many of these methods typically 
require a minimum of 10 to 100 ng of high-quality DNA obtained from whole blood 
specimens.
Although large quantities of high-quality DNA can be obtained from whole blood collected 
by venipuncture, the costs of collection, transport, and storage are important considerations. 
Use of alternative specimens, such as dried blood spots (DBS) and buccal cells that are less 
invasive than whole blood, has become widely accepted. Buccal cell collection is a cost-
effective method that has become increasingly popular in large-scale studies and is 
particularly suitable for infants, young children, and widely dispersed populations.12 DBSs 
are easily transported and stored and are obtained on all newborns in the United States 
through newborn screening programs. If properly stored, DBSs are stable for many years.13
We used pyrosequencing, a solution-based, fluorescent, real-time DNA sequencing method, 
to determine the relative copy number of the 22q11.2 region. During the reaction, 
pyrophosphate is stoichiometrically split off from the deoxynucleoside triphosphate as it is 
incorporated into the growing strand. This initiates a reaction cascade leading to quantifiable 
light emission. The resulting peak heights are directly proportional to the number of 
individual nucleotides incorporated, making it a quantitative technology with the added 
benefit of providing confirmatory context sequence data.14 We designed an assay that 
targets the ubiquitin fusion degradation (UFDL1) gene located within both the commonly 
deleted 3-Mb region and the nested 1.5-Mb deletion on chromosome 22 (Chr22). The assay 
also targets a reference sequence on chromosome 18 (Chr18) that serves as an undeleted 
control. The high degree of homology of the reference sequence to the Chr22 region allows 
for co-amplification of both loci using a single PCR primer pair and one pyrosequencing 
primer. After the two primary amplicons are generated, the sequencing primer is used to 
extend the PCR products by addition of nucleotides in a specific order, according to the 
known sequence. The amplicons differ from each other at several nucleotide positions, and 
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the relative contribution of nucleotides specific to Chr18 and Chr22 is then used to 
determine the copy number. This approach is based on the paralogue ratio test,15–17 and 
proved to be reliable even for DNA from buccal and DBS specimens, which typically yield 
lower quantity and quality DNA compared with whole blood.13,18
Materials and Methods
Assay Design
To identify a homologous reference sequence, we compared the genomic DNA sequence of 
genes located within the 3-Mb and the nested 1.5-Mb deletion (Figure 1A) against the entire 
human genome sequence using the Basic Local Alignment Search Tool (BLAST; http://
blast.ncbi.nlm.nih.gov/Blast.cgi, last accessed April 30, 2014). A 780-bp intergenic region 
on Chr18 was identified, which shares 93% identity to an exonic region in the UFD1L gene 
on Chr22. A search of the Database of Genomic Variants (http://dgv.tcag.ca/dgv/app/home, 
last accessed April 30, 2014) showed no known deletions in the Chr18 region. This is a 
curated database of structural variation in >14,000 unique samples in approximately 44 
different populations. In recent years, most data have been generated by high-resolution 
microarrays and next-generation sequencing technologies, which contributed to significant 
improvements in accuracy.19 Primer location and sequences used for the pyrosequencing 
assay are shown in Figure 1B. The PCR products contained several nucleotide sequence 
differences between the two loci. The forward sequencing primer was positioned upstream 
of two key nucleotide site differences. A selective nucleotide dispensation order was used to 
generate Chr22- and Chr18-specific peaks that allow for clear distinction between the two 
loci in the resulting pyrograms. Negative nucleotide dispensations were inserted to serve as 
internal controls for nucleotide misincorporation. All peaks in the pyrograms were used to 
ensure the specificity of the assay. The pyrosequencing assay was designed using PSQ 
Assay Design software version 1.0 (Biotage AB, Uppsala, Sweden). The specificity of the 
PCR primer pairs was checked using University of California, Santa Cruz, Genome 
Bioinformatics in silico PCR (http://genome.ucsc.edu/cgi-bin/hgPcr?command=start, last 
accessed April 30, 2014) to confirm that only the targeted Chr22 and Chr18 regions would 
be amplified.
Data Analysis for Pyrosequencing Assay
Peak height values for Chr22- and Chr18-specific peaks were exported from the PSQHS 
96A Software version 1.2 (Biotage AB) into a text file, which was imported into Microsoft 
Excel (Redmond, WA) for peak height ratio calculations. Two peak height ratios were 
determined: the C/T ratio was obtained by dividing the Chr22-specific peak height at 
dispense 3 (C) by the Chr18-specific peak height at dispense 2 (T), and the A/G peak height 
ratio was obtained by dividing the Chr22-specific peak height at dispense 24 (A) by the 
Chr18-specific peak height at dispense 23 (G). Theoretical ratios of 0.5, 1.0, and 2.0 are 
expected for deleted, nondeleted, and duplicated samples, respectively. All graphs and 
calculations for mean, median, coefficient of variation (CV), and SD were performed within 
Microsoft Excel.
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We performed initial assay development and validation using cell line–derived DNA from 
Coriell Cell Repositories (Camden, NJ). Samples included FISH-confirmed 22q11.2 deleted 
DNA from patients (n = 3) with clinically diagnosed DGS (NA07215 or NA13325) and 
velocardiofacial syndrome (NA07939). DNA from the Human Variation Collection (n = 
180) served as nondeleted controls and included samples from the SNP500 Cancer Resource 
panel (n = 108; SNP500V), African American panel (n = 24; HD24AA), European 
Caucasian panel (n = 24; HD24EC), and Han Chinese panel (n = 24 HD24CHI). We also 
evaluated whole blood, DBS, and buccal cell specimens obtained from patients attending the 
Southeastern Regional Center for 22q (Emory University, Atlanta, GA). This set of 
specimens consisted of paired whole blood and buccal swabs obtained from 19 patients and 
one nonpaired patient buccal swab. DBSs were obtained from an additional nine patients. 
The Emory Cytogenetics laboratory confirmed the presence of the 22q11.2 deletion in all 
patients by FISH. We also included buccal samples (n = 88) and DBS (n = 15) from subjects 
who lack the deletion. Last, two DNA samples with verified 22q11.2 microduplications 
were obtained from the MGL Cytogenetic and Microarray Laboratories at Baylor College of 
Medicine (Houston, TX). The duplication was confirmed by two-color FISH and array-
comparative genomic hybridization. All samples were de-identified before receipt. Samples 
were obtained with informed consent under study protocols with Institutional Review Board 
approval at Emory University and Baylor College of Medicine. The Centers for Disease 
Control and Prevention’s roles in laboratory analysis of de-identified samples did not 
constitute engagement in human subject research.
DNA Extraction
DNA was isolated from 4-mL whole blood specimens using Gentra Puregene reagents 
(Qiagen, Valencia, CA), according to the manufacturer’s instructions. DNA from one 3.2-
mm DBS punch was isolated using the Qiagen Investigator kit, according to the 
manufacturer’s protocol, with a 60-µL elution volume. Buccal swabs were collected using 
cytobrushes, and DNA was extracted by phenol-chloroform.20 Genomic DNA yields were 
assessed by quantitative real-time PCR using the human RNase P gene. Primer sequences 
are available on request. DNA concentrations were determined, in duplicate, using the ABI 
7500 Sequence Detection System and established manufacturer’s protocols (Applied 
Biosystems, Foster City, CA).
MLPA of Nondeleted Controls
The copy number of the 22q11.2 region in non–FISH-confirmed Coriell, buccal, and DBS 
samples that served as nondeleted controls was analyzed by MLPA. The SALSA P250-A1 
MLPA-DGS test kit (MRC-Holland, Amsterdam, the Netherlands) was used following the 
manufacturer’s instructions. The P250 probe mix is a high-density kit that contains 48 
different probes and is designed to detect deletions and duplications in the 22q11.2 region. 
All runs included DNA from three normal controls to calibrate unknown samples. The 
reaction products were detected with an ABI Prism 3100 Genetic Analyzer (Applied 
Biosystems). The ABI GeneMapper software version 3.5 (Applied Biosystems) was used to 
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size the PCR products and to obtain peak areas. These data were imported into Coffalyser 
Software version 9.4 (MRC-Holland) for MLPA analysis.
PCR Optimization
PCR conditions were evaluated for each specimen type using 5-ng input DNA from deleted, 
nondeleted, and duplicated samples. All reactions were performed in a final volume of 20 
µL containing 0.5 µmol/L of each primer (Integrated DNA Technologies, Coralville, IA) and 
a commercial PCR master mix (described below) at 1× concentration. The optimum 
annealing temperature was 60.5°C for DNA from blood, cell lines, and buccal specimens 
and 63.5°C for DBS, as determined by gradient cycling (Eppendorf Mastercycler Gradient; 
Eppendorf, Hauppauge, NY), ranging from 55.0°C to 64.0°C. We chose the highest 
annealing temperature that maintained good separation between deleted and nondeleted C/T 
ratios, yet remained close to theoretical values of 1.0 and 0.5 for nondeleted and deleted, 
respectively.
Thermal cycling conditions were as follows: 95°C for 10 minutes, 40 cycles at 94°C for 10 
seconds, followed by either 60.5°C or 63.5°C for 20 seconds, 72°C for 1 minute, and a final 
extension at 72°C for 2 minutes. All PCR runs included a no template control, a deleted 
DNA control, and a nondeleted DNA control derived from the same specimen type as the 
test samples.
Three PCR master mixes were evaluated: i) AmpliTaq Gold PCR Master Mix (Applied 
Biosystems), ii) Amplitaq Gold PCR Master Mix with the addition of PCRboost 
(Biomatrica, San Diego, CA), and iii) PyroMark PCR Kit (Qiagen). A subset of blood and 
cell line–derived DNA (n = 19 deleted samples, and n = 147 nondeleted samples) was 
amplified using all three master mixes. On the basis of these results, buccal DNA samples (n 
= 6 deleted, and n = 16 nondeleted) were amplified using two of the master mixes: Amplitaq 
Gold PCR Master Mix with PCRboost and Pyro-Mark PCR Kit.
Pyrosequencing
PCR products (5 µL) were processed in a 96-well format for pyrosequencing analysis 
following the standard manufacturer’s protocol (Qiagen). Single-stranded DNA was 
prepared by immobilization of the biotinylated PCR product onto streptavidin-coated 
Sepharose high-performance beads (GE Healthcare, Piscataway, NJ) with subsequent 
removal of nonbiotinylated single strands using the Vacuum Prep workstation (Biotage AB). 
The pyrosequencing reaction was conducted in a PSQ 96HSA System (Biotage AB) using 
PyroMark Gold reagents (Qiagen).
Analytic Sensitivity and Reproducibility
Sensitivity of the optimized PCR system was investigated by limiting dilution experiments 
using DNA from whole blood (n = 2 deleted), cell lines (n = 2 nondeleted, n = 1 deleted), 
buccal cells (n = 3 nondeleted, n = 3 deleted), and DBS (n = 3 nondeleted, n = 2 deleted). 
Serially diluted DNA ranging from 0.125 to 2.0 ng was amplified in quadruplicate using a 
PyroMark PCR kit followed by pyrosequencing. Mean C/T ratios (Chr22/Chr18 ratio) were 
determined for each quantity of input DNA. We evaluated assay reproducibility by 
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amplifying replica sets of DNA from 88 nondeleted and 20 deleted buccal samples on 2 
different days.
Results
MLPA Confirmation of Nondeleted Controls
MLPA analysis of Coriell and buccal DNA samples used as nondeleted controls confirmed 
the absence of the 22q11.2 deletion in all samples. Analysis of DNA from DBS was 
unsuccessful by MLPA, most likely because of the limited quantity and quality of the DNA 
necessary for this method. However, 4 of 15 nondeleted control DBS samples were FISH 
confirmed. Pyrosequencing analyses between these four samples and the remaining 11 non–
FISH-confirmed controls were concordant for the absence of the 22q11.2 deletion.
Assay Design and Interpretation
A quantitative pyrosequencing assay was designed for the relative quantitation of the 
22q11.2 microdeletion region using a homologous region of Chr18 as a reference. The 
choice of a reference sequence with high homology allowed us to amplify both targets in a 
single tube using the same PCR and sequencing primers. The relative quantities of 
amplification products were determined by pyrosequencing through short regions that differ 
between the 22q11.2 deleted region and the Chr18 reference sequence. The resulting signal 
peak pattern (pyrogram) is a product of the two sequencing reactions that are performed 
simultaneously. The three types of peaks that were generated were peaks specific for the 
22q11.2 region, peaks specific for the Chr18 region, and peaks that represent a combined 
signal from both regions. We determined the relative copy number of the 22q11.2 region by 
calculating the ratio between Chr22- and Chr18-specific peaks.
Representative pyrograms from selected nondeleted, deleted, and duplicated samples are 
shown in Figure 2. The nondeleted (2N) sample (Figure 2A) produced Chr22- and Chr18-
specific peak heights that were similar in magnitude to each other. The deleted (hemizygous 
or 1N) sample (Figure 2B) showed Chr22-specific peaks that were approximately half the 
height of Chr18-specific peaks, whereas the duplicated (3N) sample (Figure 2C) showed 
Chr22-specific peaks that were approximately twice the height of Chr18-specific peaks. 
These results are consistent with the expected peak height ratios for each 22q11.2 copy 
number status. The consistent peak heights for the Chr18 region in all samples showed no 
evidence of copy number variability.
The distribution of C/T peak height ratios is shown in Figure 3 scatter plots. Cell line and 
whole blood–derived DNA segregated into two groups (Figure 3A). The deleted samples 
clustered into one group with a median (mean ± SD) peak height ratio of 0.44 (0.44 ± 0.05), 
and the nondeleted samples clustered into a second group with a median (mean ± SD) peak 
height ratio of 1.03 (1.04 ± 0.07). The two duplication samples gave a mean peak height 
ratio value of 1.72. Likewise, DBS and buccal DNA samples correctly segregated into two 
nonoverlapping groups according to their deletion status (Figure 3, B and C). DBS DNA 
gave a median (mean ± SD) peak height ratio of 0.54 (0.53 ± 0.08) for deleted samples and 
1.03 (1.0 ± 0.1) for nondeleted samples. Median (mean ± SD) peak height ratios in buccal 
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DNA were 0.57 (0.57 ± 0.02) and 1.22 (1.23 ± 0.05) for deleted and nondeleted samples, 
respectively. All pyrosequencing results from deleted samples were 100% concordant with 
FISH assay results, and all nondeleted controls were correctly called.
In most cases, the deletion status calls on the basis of A/G peak height ratios were 
concordant with those on the basis of C/T peak height ratios; however, we observed that 
A/G ratios were less robust in discriminating between deleted and nondeleted samples. 
Receiver operating characteristic curve analysis showed 100% sensitivity and 100% 
specificity at C/T ratio cutoff values for deletion samples of 0.53, 0.65, and 0.6 for blood, 
DBS, and buccal specimens, respectively. Although receiver operating characteristic curve 
analysis also showed 100% sensitivity and 100% specificity at A/G ratio cutoff values of 
0.75 for DBS and 0.67 for buccal DNA samples, the cutoff value for blood DNA samples of 
0.6 represents 100% sensitivity and 98.9% specificity because of two observations that 
generated an overlap between deletion and nondeletion samples. The adenosine (A) 
nucleotide used in pyrosequencing is an ATP analog; therefore, peak heights generated from 
adenosine dispensations are consistently higher than those generated from addition of other 
bases.21 In addition, the pyrosequencing reaction tends to become less robust as peaks are 
generated further downstream in the sequence where the A and G peaks reside. Because of 
the aforementioned issues, the A/G site alone is not reliable for detection of the 22q11.2 
deletion. A search in the University of California, Santa Cruz, genome browser yielded 
several low-frequency single-nucleotide polymorphisms (SNPs) that reside just upstream or 
downstream of the A/G site on either Chr22 or Chr18. One SNP on Chr22 (rs199813245) 
occurred in 1 (0.046%) of 2179 samples tested and may be a private mutation. Two other 
SNPs on Chr18, rs138982743 and rs78664154, have a prevalence of 3 (0.138%) of 2179 
and 15 (0.653%) of 2296, respectively. Because these SNPs do not interfere with the 
upstream diagnostic C/T site, there would be no effect on final assay outcomes.
Assay Optimization
Gradient cycler experiments showed minimal influence of PCR annealing temperature on 
peak height ratios in DNA from whole blood, cell line, DBS, and buccal cell specimens. We 
selected annealing temperatures that provided the greatest separation between nondeleted 
and deleted C/T ratios, which were also closest to the theoretical values of 1.0 and 0.5 for 
nondeleted and deleted, respectively. This was slightly different for DNA from blood, cell 
lines, and buccal specimens (60.5°C) compared with DNA from DBS (63.5°C).
A summary of the PCR master mix evaluation is shown in Table 1. The SD and CV of C/T 
ratios obtained from nondeleted blood, cell line, and buccal DNA samples were significantly 
smaller (P < 0.0001, Student’s t-test) when the PyroMark PCR kit was used compared with 
both Amplitaq Gold and Amplitaq Gold plus PCRboost master mixes. Likewise, the SD and 
CV of C/T ratios for deleted buccal DNA samples were significantly smaller (P < 0.0023, 
Student’s t-test) when the PyroMark PCR kit was used compared with the Amplitaq Gold 
plus PCRboost master mix. Although results from deleted blood and cell line DNA samples 
had lower variability using the PyroMark PCR kit, they did not reach statistical significance. 
This underlines the importance of optimizing assays for each specimen type to achieve the 
most reliable results.
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Analytic Sensitivity and Interassay Variation
The sensitivity of the assay was evaluated by performing limiting dilution experiments 
(Figure 4). The deletion status could accurately be determined using as little as 0.5 ng of 
DNA from whole blood, cell lines, and buccal cells. At lower amounts of input DNA, the 
C/T ratios of deleted samples overlapped with those of nondeleted samples, which prevented 
an unambiguous determination of the deletion status. Although the C/T ratios between 
deleted and nondeleted samples were nonoverlapping for 1.0- and 0.5-ng input DNA from 
DBS, the cutoff values were close (0.74/0.79 and 0.77/0.85, respectively). This amount of 
input DNA should be used with caution; otherwise, 2.0-ng input DNA is most reliable in this 
case. Reproducibility was assessed by performing replica runs on different days using DNA 
from deleted and nondeleted buccal specimens. A pairwise comparison of the two assays is 
shown graphically in Figure 5. The scatter plot shows that the data for the two assays lie on 
the line y = x, which indicates good agreement. Both assays were able to accurately 
distinguish the deleted from the nondeleted samples.
Discussion
The goal of this study was to develop a robust and accurate screening tool for the detection 
of the 22q11DS that could reliably be used in population-based studies that collect 
alternative specimens, such as dried blood spots and buccal swabs. We designed a 
pyrosequencing assay that coamplifies a region of the ubiquitin fusion degradation (UFDL1) 
gene located within the commonly deleted regions on Chr22 and a highly homologous 
reference sequence on Chr18. Only a single PCR primer pair and one pyrosequencing 
primer are needed, and two nucleotide sequence differences between the two amplicons are 
used to determine copy number of the 22q11.2 region. Pyrosequencing has been widely used 
for the analysis of genetic variations, such as SNPs, insertions/deletions, short repeats, and 
gene copy number. It has several advantages over traditional methods for genotyping. The 
technique offers high accuracy, flexibility, automation, and parallel processing (96 samples 
in a single plate). Once a PCR product is obtained, the simple purification steps can be 
completed in 5 to 10 minutes and subsequent sequencing data can be obtained in 15 minutes. 
For increased throughput, a plate-stacking hotel can feed up to 10 plates in succession into 
the sample sequencing chamber. This method is cost-effective in that it obviates the need for 
electrophoresis, size separation, labeled nucleotides, or labeled primers (except one 
biotinylated PCR primer). Jansson et al22 and Söderbäck et al23 have also successfully 
applied pyrosequencing technology for gene copy analysis of the GSTM1 gene and the 
CY2PD6 gene, respectively. A related approach has been described by Deutsch et al15 for 
the diagnosis of trisomy 21.
In our assay, we used primers that perfectly match both Chr22 and Chr18 targets to increase 
the likelihood that amplification efficiencies would be nearly identical.23 Neither deletions 
nor duplications have been reported for the Chr18 reference region, which shares 
approximately 93% homology to the UFD1L region at the nucleotide level. This design 
simplifies method validation, assay setup, and data analysis. To our knowledge, this is the 
first report describing the detection of the 22q11.2 deletion that uses a highly homologous 
region on a separate gene as the 2N reference as opposed to an unrelated (nonhomologous) 
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gene, which requires separate PCR and sequencing primers and may lead to variations in 
amplification efficiencies between the different genetic regions.
In conclusion, we developed a new assay for the reliable and accurate detection of 22q11.2 
deletions and duplications in DNA samples of lower quality and quantity from such sources 
as buccal cells and DBS. This assay is an appealing alternative to existing methods that 
often require high-quality DNA and expensive fluorescent probes. The assay offers a cost-
effective and high-throughput way in which to perform population-based screening to obtain 
more accurate prevalence and phenotypic data. This novel technique could be a useful 
method for newborn screening programs and for retrospective and prospective studies on the 
basis of a single small punch from a DBS or a single cytobrush. This assay design approach 
might also be considered for the development of assays that target atypical 22q11.2 
deletions outside the common deletion regions.
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A: Map of the 22q11.2 deleted region showing the location of the TUPLE1 FISH probe and 
UFD1L gene (hatch marked). Light gray boxes with associated Human Genome 
Organization (HUGO) gene names denote surrounding genes in this region. Dark gray boxes 
indicate locations of the four low copy repeats (LCRs) that mediate deletions of 22q11.2.10 
B: Alignment of Chr22 (UFD1L) and Chr18 target sequences. Solid arrows indicate 
forward (5′-GGATGAAGCTGGAGGCAGATT-3′) and 3′-biotinylated reverse (5′-
AATCAGCCAACAGTCCTCACTTAG-3′) PCR primers. The broken arrow indicates the 
forward sequencing primer (5′-TGGAGGCAGATTCGT-3′). Underlined nucleotides 
represent sequence differences between the two chromosomes that are detected in the 
pyrosequencing assay.
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Representative pyrograms generated by pyrosequencing. A: The expected sequence 
(forward direction) appears above the pyrogram, and the dispensation order is shown under 
each pyrogram. Dispensations 1 and 4 are negative and serve as internal controls for 
nucleotide misincorporation. The Chr18-specific nucleotide peaks (dispensations 2 and 23, 
green arrows) and the Chr22-specific nucleotide peaks (dispensations 3 and 24, red 
arrows). Pyrogram for a nondeleted DNA sample from buccal cells shows Chr18- and 
Chr22-specific peaks of approximate equivalent height (A), for a 22q11.2 deletion DNA 
sample from buccal cells shows Chr22-specific peak heights decreased by approximately 
half of Chr18-specific peak heights (B), and for a 22q11.2 duplication DNA sample from 
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whole blood shows Chr22-specific peak heights increased approximately twofold higher 
than that of Chr18-specific peak heights (C).
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Scatter plots show C/T ratios for nondeleted, deleted, and duplicated (whole blood only) 
DNA samples from whole blood and cell lines (A), DBS (B), and buccal cells (C). 
Nondeleted (two copies), deleted (one copy), and duplicated (three copies) subjects are 
indicated by theoretical C/T ratios of 1.0, 0.5, and 1.5, respectively. Duplication samples 
(circles), nondeletion samples (diamonds), and deletion samples (X marks) are shown.
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C/T peak height ratios for nondeleted and deleted samples as a function of input DNA (ng) 
extracted from blood and cell lines (A), DBS (B), and buccal cells (C).
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Pairwise graph shows reproducibility between duplicate assay runs on different days using 
DNA extracted from buccal cells. Assay 1 data (diamonds) and assay 2 data (circles). C/T 
ratio data points for assay 1 versus assay 2 fall along the line y = x, which shows strong 
agreement between the two. There is a clear separation between nondeleted and deleted C/T 
ratios.
Koontz et al. Page 16































































































































































































































































































































J Mol Diagn. Author manuscript; available in PMC 2015 July 27.
